naftifine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1872 | 65472-88-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
allylamine der; RN given refers to unlabeled parent cpd
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 29, 1988 | FDA | MERZ PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AE22 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
| FDA CS | M0000751 | Allylamine |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| CHEBI has role | CHEBI:59285 | squalene monooxygenase inhibitors |
| CHEBI has role | CHEBI:83317 | sterol biosynthesis inhibitors |
| FDA EPC | N0000175874 | Allylamine Antifungal |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tinea pedis | indication | 6020002 | DOID:12403 |
| Tinea corporis | indication | 84849002 | |
| Tinea cruris | indication | 399029005 | |
| Pityriasis versicolor | off-label use | 56454009 | DOID:9060 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.87 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 2% | NAFTIN | SEBELA IRELAND LTD | N204286 | June 27, 2013 | RX | GEL | TOPICAL | 9161914 | Jan. 31, 2033 | TREATMENT OF FUNGAL INFECTIONS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Enzyme | Ki | 5.82 | CHEMBL | |||||
| Squalene monooxygenase | Enzyme | WOMBAT-PK | |||||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.06 | CHEMBL | |||||
| Squalene epoxidase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| C-8 sterol isomerase | Enzyme | Ki | 6.51 | CHEMBL | |||||
| Squalene monooxygenase | Enzyme | IC50 | 6.50 | CHEMBL | |||||
| Dehydrosqualene desaturase | Enzyme | IC50 | 6.53 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019850 | VUID |
| N0000171577 | NUI |
| D00883 | KEGG_DRUG |
| 65473-14-5 | SECONDARY_CAS_RN |
| 4019526 | VANDF |
| 4019850 | VANDF |
| C0068367 | UMLSCUI |
| CHEBI:7451 | CHEBI |
| CHEMBL626 | ChEMBL_ID |
| DB00735 | DRUGBANK_ID |
| CHEMBL1200493 | ChEMBL_ID |
| C029178 | MESH_SUPPLEMENTAL_RECORD_UI |
| 47641 | PUBCHEM_CID |
| 4588 | INN_ID |
| 4FB1TON47A | UNII |
| 31476 | RXNORM |
| 234377 | MMSL |
| 5146 | MMSL |
| 002929 | NDDF |
| 002930 | NDDF |
| 13800009 | SNOMEDCT_US |
| 372655002 | SNOMEDCT_US |
| 47408003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| NAFTIFINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1510 | GEL | 10 mg | TOPICAL | ANDA | 17 sections |
| NAFTIFINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1512 | CREAM | 20 mg | TOPICAL | ANDA | 23 sections |
| Naftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0259-4126 | CREAM | 10 mg | TOPICAL | NDA | 19 sections |
| Naftifine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1362 | CREAM | 10 mg | TOPICAL | ANDA | 19 sections |
| Naftifine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1368 | CREAM | 20 mg | TOPICAL | ANDA | 25 sections |
| Naftifine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1376 | GEL | 20 mg | TOPICAL | ANDA | 25 sections |
| Naftifine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1376 | GEL | 20 mg | TOPICAL | ANDA | 25 sections |
| Naftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54766-770 | GEL | 10 mg | TOPICAL | NDA | 19 sections |
| Naftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54766-772 | GEL | 2 g | TOPICAL | NDA | 26 sections |
| Naftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2185 | GEL | 10 mg | TOPICAL | NDA | 19 sections |
| Naftin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-2240 | CREAM | 10 mg | TOPICAL | NDA | 19 sections |
| Naftifine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70700-161 | CREAM | 20 mg | TOPICAL | ANDA | 24 sections |